Given the high prevalence of OSA and the elevated risk for AD in individuals with DS, there is a critical need to understand whether OSA or sleep disruptions are related to elevated levels of Aβ or tau burden or AD symptomatology in models controlling for age in adults with DS. The gene discussed is MAPT; the disease is Alzheimer disease.